ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Does the C1q Assay Predict the Result of Lymphocyte Flow Cross-Match (FCxM) in Potential Renal Transplant Recipients With HLA-DSA and AHG-CDC CxM negative?

J. Arreola-Guerra, A. de Santiago, A. Arvizu, N. Gonzalez-Tableros, M. Lopez, M. Vilatoba, L. Morales-Buenrostro, J. Alberu, N. Castelan.

1Transplantation, 1aNephrology-Mineral Metabolism, Inst Nal de Ciencias Medicas y Nutricion SZ, Mexico City, Mexico.

Meeting: 2015 American Transplant Congress

Abstract number: A115

Keywords: Alloantibodies, Flowcytometry crossmatching, Kidney transplantation, Sensitization

Session Information

Session Name: Poster Session A: Kidney Antibody Mediated Rejection

Session Type: Poster Session

Date: Saturday, May 2, 2015

Session Time: 5:30pm-7:30pm

 Presentation Time: 5:30pm-7:30pm

Location: Exhibit Hall E

Background. The presence of pre-transplant HLA donor specific antibodies (DSA) is a recognized risk factor for acute rejection. However, due to the test's (LUMINEX) high specificity, it is not possible to determine which DSA(s) are pathogenic. The correlation between the DSA mean fluorescence intensity (MFI) and the FCxM result have been demonstrated in different series. The C1q assay may be an alternative to distinguish complement-fixing (pathogenic) vs. non-complement-fixing HLA antibodies. Aim: To establish the DSA MFI level with the best sensitivity and specificity in predicting FCxM and compare it with the C1q assay's predictive capacity in patients with DSA(s) and AHG-CDC CxM negative. Methods. We used cryopreserved (-70°C) sera from potential renal transplant recipients (PRT), containing DSAs against their respective donors – all had negative AHG-CDC CxM and either positive or negative FCxM. A MFI ROC curve was plotted and the point of best concordance with FCxM was determined. Sera were evaluated with the LUMINEX C1q assay. The sensitivity and specificity of the C1q assay were determined as well as that of the DSA with a pre-determined MFI for FCxM. Results: Fifty-eight PRT were evaluated, 5 of which had 2 potential donors. We analyzed 63 tests of which 33 (52.3%) had a positive FCxM. The average MFI of the dominant DSA was 6,337 MFI. A MFI of 2300 performed best.

C1q Ab   CI 95%
Sensitivity 80% 65.32 – 94.68
Specificity 82.14% 66.17 – 98.11
Positive predictive value 84.85% 71.1 – 98.6
Negative predictive value 76.6% 59.87 – 93.47
Kappa 0.617  
Concordance 80.95%  
DSA MFI> 2300   IC 95%
Sensitivity 75.76 59 – 91.89
Specificity 76.67 59.87 – 93.47
Positive predictive value 78.13 62.24 – 94.01
Negative predictive value 74.19 57.18 – 91.21
Kappa 0.523  
Concordance 76.19%  
Table I: Sensitivity, specificity and predictive values of C1q binding Abs and DSA with MFI > 2300

When joining the C1q assays with the DSA >2300 MFI, sensitivity improved but specificity decreased.(Sens. 96.97% (CI 89.6-100) Spec. 60% (40 -79%) PPV 72.7% (58 – 87) NPV 93.33% (82.06 – 100). Conclusions: The C1q assay is a better predictor of the FCxM result when compared with only the presence of DSA. DSA values with a MFI <2300 and not binding C1q, can be considered to yield a negative FCxM.

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Arreola-Guerra J, Santiago Ade, Arvizu A, Gonzalez-Tableros N, Lopez M, Vilatoba M, Morales-Buenrostro L, Alberu J, Castelan N. Does the C1q Assay Predict the Result of Lymphocyte Flow Cross-Match (FCxM) in Potential Renal Transplant Recipients With HLA-DSA and AHG-CDC CxM negative? [abstract]. Am J Transplant. 2015; 15 (suppl 3). https://atcmeetingabstracts.com/abstract/does-the-c1q-assay-predict-the-result-of-lymphocyte-flow-cross-match-fcxm-in-potential-renal-transplant-recipients-with-hla-dsa-and-ahg-cdc-cxm-negative/. Accessed May 8, 2025.

« Back to 2015 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences